Arjun Gururaj, MD
Cardiovascular Disease · Las Vegas, NVNPI 1407801624
Payments from drug & device makers
Across 1,145 payments — averaging $348.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acutus Medical, Inc.$123K
- Medtronic$106K
- Abbott$86K
- Biotronik Inc.$32K
- Cardiofocus, Inc.$19K
- Cvrx, Inc.$16K
- plus $17K from 31 others
What the payments were for
- Consulting fees$188,79547%
- Speaking & faculty fees$91,99123%
- Travel & lodging$57,26414%
- Food & beverage$61,00515%
- Education$1730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acutus Medical, Inc. | 119 | $122,874 |
| Medtronic(2 entities) | 213 | $106,439 |
| Abbott | 267 | $86,191 |
| Biotronik Inc. | 64 | $31,719 |
| Cardiofocus, Inc. | 84 | $18,905 |
| Cvrx, Inc. | 45 | $16,440 |
| Impulse Dynamics (USA) Inc. | 23 | $2,846 |
| Biosense Webster, Inc. | 33 | $2,624 |
| Cardiva Medical, Inc. | 65 | $1,599 |
| ZOLL Respicardia, Inc. | 9 | $1,537 |
| Inspire Medical Systems, Inc. | 28 | $1,515 |
| Boston Scientific | 24 | $1,430 |
| Atricure, Inc. | 13 | $1,220 |
| Novartis | 26 | $519 |
| E.r. Squibb & Sons, L.L.C. | 25 | $515 |
| Merck | 21 | $465 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $428 |
| Johnson & Johnson | 19 | $283 |
| Esperion Therapeutics, Inc. | 6 | $233 |
| Amgen | 25 | $190 |
| Preventice Services, LLC | 1 | $170 |
| Portola Pharmaceuticals, LLC | 2 | $153 |
| Sanofi-aventis U.S. LLC | 3 | $118 |
| Lexicon Pharmaceuticals, Inc. | 4 | $113 |
| Penumbra, Inc. | 1 | $97 |
| Livanova USA, Inc. | 1 | $96 |
| Itamar Medical Inc | 1 | $85 |
| AstraZeneca | 2 | $82 |
| Pfizer | 4 | $62 |
| Boehringer Ingelheim | 3 | $58 |
| Cordis US CORP. | 1 | $58 |
| Novo Nordisk | 2 | $35 |
| Bridgebio Pharma, Inc. | 1 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADVISOR$20,567
- AFFERA MAPPING SYSTEM$18,848
- AMPLATZER AMULET$15,551
- Barostim Neo System$15,404
- HeartLight System$13,622
- EnSite Precision Cardiac Mapping System$13,544
- NA$8,020
- ENSITE PRECISION$7,938
- Advisor Catheter$5,700
- OPTIMIZER$4,061
- AVEIR$2,732
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$1,366
- remede System$1,305
- ENSITE$1,270
- PulseSelect$937
- VIEWMATE$873
- BioMonitor$859
- Carto 3 System$854
- TactiCath Quartz CFA Catheter$840
- Edora 8 DR-T$799
How this compares
$399,229 in reported general payments places this provider in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 306 | $351,391 |
| XareltoRivaroxaban | 156 | $192,178 |
| EntrestoSacubitril/Valsartan | 152 | $191,563 |
| MultaqDronedarone Hcl | 54 | $90,488 |
| VerquvoVericiguat | 43 | $51,735 |
| Repatha SureclickEvolocumab | 36 | $38,296 |
| JardianceEmpagliflozin | 29 | $37,098 |
| FarxigaDapagliflozin Propanediol | 18 | $25,475 |
| Carvedilol | 195 | $1,501 |
| Metoprolol Succinate | 86 | $1,144 |
| Atorvastatin Calcium | 124 | $1,137 |
| Ranolazine ErRanolazine | 17 | $1,123 |
| Losartan Potassium | 82 | $1,099 |
| Amiodarone Hcl | 50 | $1,083 |
| Rosuvastatin Calcium | 68 | $1,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $62 | $351,391306 claims |
| Johnson & JohnsonXarelto | $283 | $192,178156 claims |
| NovartisEntresto | $519 | $191,563152 claims |
| Sanofi-aventis U.S. LLCMultaq | $118 | $90,48854 claims |
| MerckVerquvo | $465 | $51,73543 claims |
| Boehringer IngelheimJardiance | $58 | $37,09829 claims |
| AstraZenecaFarxiga | $82 | $25,47518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Ramprasad DandillayaLas Vegas$1.8M
- Chowdhury AhsanLas Vegas$1.4M
- Navid KazemiLas Vegas$156K
- Branavan UmakanthanLas Vegas$109K
- Sanjay MalhotraLas Vegas$101K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Rafael ValenciaLas Vegas$52K
- Salvador BorromeoLas Vegas$45K
- William ReshLas Vegas$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.